{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:39:07Z","timestamp":1765280347263,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.dsx.2022.102657","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T19:04:37Z","timestamp":1666983877000},"page":"102657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dose-dependent efficacy and safety of licogliflozin on obese adults: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4089-9749","authenticated-orcid":false,"given":"Alaa Mohamed","family":"Zaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina Essam","family":"Abo-Elnour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yomna Emad","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rehab Yosri","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moaz Khaled","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toka","family":"Elboraay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim Abdelmonaem","family":"Abdelhaleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2012","series-title":"Obesity and overweight","key":"10.1016\/j.dsx.2022.102657_bib1"},{"key":"10.1016\/j.dsx.2022.102657_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.dsx.2016.06.017","article-title":"Obesity and diabetes: an update","volume":"11","author":"Verma","year":"2017","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"10.1016\/j.dsx.2022.102657_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1575-0922(09)73516-8","article-title":"Obesity and diabetes","volume":"56","author":"Lois","year":"2009","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.dsx.2022.102657_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5114\/aoms.2016.58928","article-title":"Obesity and inflammation: the linking mechanism and the complications","volume":"4","author":"Ellul","year":"2017","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.dsx.2022.102657_bib5","first-page":"1","article-title":"Efficacy and safety of efpeglenatide in adults with obesity and its associated metabolic disturbance: a systematic review and meta-analysis of randomized controlled trials","author":"Abdelhaleem","year":"2021","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2022.102657_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.dsx.2022.102657_bib8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cpt.1840","article-title":"Investigation and management of stool frequency and consistency associated with SGLT1 inhibition by reducing dietary carbohydrate: a randomized trial","volume":"108","author":"He","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dsx.2022.102657_bib9","first-page":"E117","article-title":"Improved glycemic control in mice lacking Sglt1 and Sglt2","volume":"304","author":"Powell","year":"2013","journal-title":"Am J Physiol Metab"},{"key":"10.1016\/j.dsx.2022.102657_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2022.102657_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/dom.13630","article-title":"What does sodium-glucose co-transporter 1 inhibition add: prospects for dual inhibition","volume":"21","author":"Dominguez Rieg","year":"2019","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2022.102657_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/00498254.2020.1867331","article-title":"Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1\/2, in rats, dogs, and humans","volume":"51","author":"Wang-Lakshman","year":"2021","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dsx.2022.102657_bib13","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/dom.13654","article-title":"The effects of licogliflozin, a dual SGLT1\/2 inhibitor, on body weight in obese patients with or without diabetes","volume":"21","author":"He","year":"2019","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2022.102657_bib14","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/oby.22764","article-title":"Licogliflozin, a novel SGLT1 and 2 inhibitor: body weight effects in a randomized trial in adults with overweight or obesity","volume":"28","author":"Bays","year":"2020","journal-title":"Obesity"},{"year":"2019","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","key":"10.1016\/j.dsx.2022.102657_bib15"},{"key":"10.1016\/j.dsx.2022.102657_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"18","author":"Page","year":"2021","journal-title":"PLoS Med"},{"year":"2020","series-title":"Version 5.4, the Cochrane collaboration","key":"10.1016\/j.dsx.2022.102657_bib17"},{"key":"10.1016\/j.dsx.2022.102657_bib18","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/dom.14006","article-title":"Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity","volume":"22","author":"Yokote","year":"2020","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2022.102657_bib19","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/bcp.14248","article-title":"Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure","volume":"86","author":"de Boer","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dsx.2022.102657_bib20","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.dsx.2022.102657_bib21","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/17425255.2018.1551877","article-title":"The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments","volume":"14","author":"Garcia-Ropero","year":"2018","journal-title":"Expet Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.dsx.2022.102657_bib22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.dsx.2022.102657_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/dom.14555","article-title":"Sotagliflozin for patients with type 2 diabetes: a systematic review and meta-analysis","volume":"24","author":"Avgerinos","year":"2022","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2022.102657_bib24","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the north American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2022.102657_bib25","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1089\/dia.2018.0081","article-title":"Combined SGLT1 and SGLT2 inhibitors and their role in diabetes care","volume":"20","author":"Danne","year":"2018","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.dsx.2022.102657_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13336","article-title":"Sodium-glucose co-transporter 2 inhibitors on weight change and cardiometabolic profiles in individuals with overweight or obesity and without diabetes: a meta-analysis","volume":"22","author":"Wong","year":"2021","journal-title":"Obes Rev"},{"key":"10.1016\/j.dsx.2022.102657_bib27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2022.102657_bib28","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1111\/dom.14495","article-title":"Licogliflozin versus placebo in women with polycystic ovary syndrome: a randomized, double-blind, phase 2 trial","author":"Tan","year":"2021","journal-title":"Diabetes Obes Metabol"},{"year":"2006","series-title":"I\u00a0obesity task. The AsiaPacific perspective: redefining obesity and its treatment","key":"10.1016\/j.dsx.2022.102657_bib29"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122002715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122002715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:20:07Z","timestamp":1761729607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402122002715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1871402122002715"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102657","relation":{},"ISSN":["1871-4021"],"issn-type":[{"type":"print","value":"1871-4021"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-dependent efficacy and safety of licogliflozin on obese adults: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102657"}}